Vasomotor Symptoms of Menopause (Hot Flashes) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Vasomotor Symptoms of Menopause (Hot Flashes) – Pipeline Review, H2 2017’, provides an overview of the Vasomotor Symptoms of Menopause (Hot Flashes) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vasomotor Symptoms of Menopause (Hot Flashes), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vasomotor Symptoms of Menopause (Hot Flashes) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Vasomotor Symptoms of Menopause (Hot Flashes)

The report reviews pipeline therapeutics for Vasomotor Symptoms of Menopause (Hot Flashes) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Vasomotor Symptoms of Menopause (Hot Flashes) therapeutics and enlists all their major and minor projects

The report assesses Vasomotor Symptoms of Menopause (Hot Flashes) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Vasomotor Symptoms of Menopause (Hot Flashes)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Vasomotor Symptoms of Menopause (Hot Flashes)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Vasomotor Symptoms of Menopause (Hot Flashes) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AstraZeneca Plc

EndoCeutics Inc

MenoGeniX Inc

Mithra Pharmaceuticals SA

N4 Pharma Plc

Ogeda SA

Pherin Pharmaceuticals Inc

TherapeuticsMD Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Vasomotor Symptoms of Menopause (Hot Flashes) Overview

Vasomotor Symptoms of Menopause (Hot Flashes) Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Vasomotor Symptoms of Menopause (Hot Flashes) Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Vasomotor Symptoms of Menopause (Hot Flashes) Companies Involved in Therapeutics Development

AstraZeneca Plc

EndoCeutics Inc

MenoGeniX Inc

Mithra Pharmaceuticals SA

N4 Pharma Plc

Ogeda SA

Pherin Pharmaceuticals Inc

TherapeuticsMD Inc

Vasomotor Symptoms of Menopause (Hot Flashes) Drug Profiles

(estradiol + progesterone) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(estradiol acetate + progesterone) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acolbifene hydrochloride + prasterone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Estetrol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fezolinetant Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FP-101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HBN-2 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MNGX-100 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-814 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

paroxetine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pavinetant Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PH-80HF Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Q-122 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vasomotor Symptoms of Menopause (Hot Flashes) Dormant Projects

Vasomotor Symptoms of Menopause (Hot Flashes) Discontinued Products

Vasomotor Symptoms of Menopause (Hot Flashes) Product Development Milestones

Featured News & Press Releases

Oct 13, 2017: Mithra Announces Completion of Recruitment in Donesta Phase II Study

Oct 05, 2017: TherapeuticsMD Announces Multiple Presentations Related to TX-001HR at NAMS 2017

May 15, 2017: Millendo Therapeutics Announces MLE4901 Data Presentations at European Congress of Endocrinology and Congress of the European Menopause and Andropause Society

Apr 03, 2017: TherapeuticsMD Presents Positive Phase 3 Data in Two Presentations for TX-001HR at ENDO 2017

Jan 04, 2017: Ogeda announces positive data from Phase IIa trial of fezolinetant (ESN364) in the treatment of menopausal hot flashes

Dec 20, 2016: Ogeda announces fezolinetant as INN and issuance of U.S. patent for ESN364

Dec 05, 2016: TherapeuticsMD Announces Positive Top-Line Results from Pivotal Phase 3 Replenish Trial in Postmenopausal Women with Moderate to Severe Vasomotor Symptoms (VMS) Treated with TX-001HR

Sep 14, 2016: Euroscreen SA: Completes Enrollment in Phase II trial of lead candidate ESN364 in Menopausal Hot Flashes

Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials

Oct 13, 2015: TherapeuticsMD Completes Enrollment in Phase 3 Clinical Trial of Bio-identical Oral Combination of Estradiol and Progesterone Product Candidate

Sep 23, 2015: Euroscreen launches Phase 2 clinical trial with ESN364 as the first and unique non-hormonal causal treatment for menopausal Hot Flashes

Jan 06, 2014: TherapeuticsMD Announces Milestone Achievement of 50th Site for Phase 3 Clinical Trial of TX 12-001HR to Treat Symptoms of Menopause and Provide Endometrial Protection

Oct 18, 2013: TherapeuticsMD Poster Wins First-Place Prize at the North American Menopause Society 2013 Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes) Pipeline by AstraZeneca Plc, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes) Pipeline by EndoCeutics Inc, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes) Pipeline by MenoGeniX Inc, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes) Pipeline by Mithra Pharmaceuticals SA, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes) Pipeline by N4 Pharma Plc, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes) Pipeline by Ogeda SA, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes) Pipeline by Pherin Pharmaceuticals Inc, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes) Pipeline by TherapeuticsMD Inc, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes) Dormant Projects, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes) Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports